Common stock, par value $0.01 per share
- Symbol
- ATAI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Sep 11, 2026
Current Report · Items 2.02, 9.01 · 8-K
AtaiBeckley Inc.
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 12, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided program and business updates. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K (“Form 8-K”).…
Company context
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has initiated Phase 3 activities; VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
Historical securities (1)
Registered securities in this filing
ATAIBECKLEY INC. · 8-K · Filed 2026-05-12
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On May 12, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended
March 31, 2026 and provided program and business updates. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K (“Form 8-K”).
The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 ef20072731_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 ───────────────────────────────────────────────────────────────────────────────────────────────────────── VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 ───────────────────────────────────────────────────────────────── Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029 NEW YORK, UNITED STATES - May 12, 2026 - AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical p…
Open exhibit ↗